Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

A framework for monitoring RSV prevention product effectiveness in the United States

by Jones, Jefferson M. , Fleming-Dutra, Katherine E. , Bajema, Kristina L. , Roper, Lauren E. , Slayton, Rachel , Payne, Amanda B. , Britton, Amadea , Ioannou, George N. , Dawood, Fatimah , Feldstein, Leora R. , Prill, Mila M. , Moline, Heidi , Kirking, Hannah , McMorrow, Meredith L. , Martin, Abby , Link-Gelles, Ruth , Hernandez-Romieu, Alfonso C. , Reddy, Sujan , Novosad, Shannon , Hall, Aron J. , Whitehead, Ralph D. , Hatfield, Kelly , Surie, Diya , Campbell, Angela P. , DeCuir, Jennifer , Gomes, Danica , Melgar, Michael , Aslan, Mihaela , Havers, Fiona P. , Zambrano, Laura D.

in Adult / Age / Aged / Allergy and Immunology / Centers for Disease Control and Prevention, U.S / Clinical decision making / Clinical trials / Decisions / Disease control / Disease prevention / Effectiveness / FDA approval / Hospitalization / Humans / Illnesses / Immunization / Immunization Programs / Indoor air quality / Infant / issues and policy / Long term health care / Monoclonal antibodies / Native children & youth / Native North Americans / Observational studies / Older people / Public health / Respiratory syncytial virus / Respiratory Syncytial Virus Infections - prevention & control / Respiratory Syncytial Virus Vaccines - administration & dosage / Respiratory Syncytial Virus Vaccines - immunology / Respiratory Syncytial Virus, Human - immunology / Robust control / United States - epidemiology / Vaccine Efficacy / Vaccines

2025

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

A framework for monitoring RSV prevention product effectiveness in the United States

2025

Confirm

Do you wish to request the book?

A framework for monitoring RSV prevention product effectiveness in the United States

2025

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

A framework for monitoring RSV prevention product effectiveness in the United States

Jones, Jefferson M.,

Fleming-Dutra, Katherine E.,

Bajema, Kristina L.,

Roper, Lauren E.,

Slayton, Rachel,

Payne, Amanda B.,

Britton, Amadea,

Ioannou, George N.,

Dawood, Fatimah,

Feldstein, Leora R.,

Prill, Mila M.,

Moline, Heidi,

Kirking, Hannah,

McMorrow, Meredith L.,

Martin, Abby,

Link-Gelles, Ruth,

Hernandez-Romieu, Alfonso C.,

Reddy, Sujan,

Novosad, Shannon,

Hall, Aron J.,

Whitehead, Ralph D.,

Hatfield, Kelly,

Surie, Diya,

Campbell, Angela P.,

DeCuir, Jennifer,

Gomes, Danica,

Melgar, Michael,

Aslan, Mihaela,

Havers, Fiona P.,

Zambrano, Laura D.

2025

Overview

During 2023, the Centers for Disease Control and Prevention (CDC) recommended the first respiratory syncytial virus (RSV) immunizations intended for widespread use in the United States to prevent severe RSV illness in infants and older adults. CDC, in collaboration with federal, public health, and academic partners, is conducting evaluations of real-world effectiveness of recommended RSV immunization products in the United States. Similar frameworks for evaluation are being applied to RSV vaccines and nirsevimab, a long-acting preventative monoclonal antibody, to estimate product effectiveness. The overall goal of CDC's RSV immunization effectiveness program is to generate timely and robust evidence through observational studies to inform immunization product policy decisions and other measures related to RSV prevention and control. CDC is evaluating effectiveness through high-quality, well-controlled observational studies leveraging a variety of platforms that provide robust data to inform policy decisions.

Share this book

Add to My Shelf

Publisher

Elsevier Ltd,Elsevier Limited

Subject

Adult

/ Age

/ Aged

/ Allergy and Immunology

/ Centers for Disease Control and Prevention, U.S

/ Clinical decision making

/ Clinical trials